Key result
Idarucizumab specifically and rapidly reverses dabigatran-induced anticoagulation, though it does not guarantee complete hemostasis in patients with comorbidities or recent trauma.
Population
Patients treated with dabigatran who have life-threatening bleeding or need emergency surgery or an invasive…
Design
Review
Authors
Loading...
Provides specific dabigatran reversal in emergencies but not guaranteed hemostasis; leaves open optimal strategies in comorbid or trauma patients.
Idarucizumab provides a specific and rapid reversal agent for dabigatran in cases of life-threatening bleeding or emergency surgery.
Dager et al. (2017) conducted a review in Dabigatran-related life-threatening bleeding or need for emergency surgery. Idarucizumab was evaluated. Idarucizumab specifically and rapidly reverses dabigatran-induced anticoagulation, though it does not guarantee complete hemostasis in patients with comorbidities or recent trauma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: